Home › NCT06128915
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
RecruitingPhase 4Healthy volunteers welcome
Who can join
Ages 21 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Both sexes * Have not been vaccinated with any licensed or experimental pneumococcal vaccine * Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old * Free of acute infections within the last 2 weeks * Did not take any anti-inflammatory medicine in the last week * Did not ingest alcohol in the last 24 hours * Ability and willingness to provide consent Exclusion Criteria: * Previous vaccination with any licensed or experimental pneumococcal vaccine * Known hypersensitivity to vaccination and vaccine components * Immune deficiency * Use of immune-modulating or suppressive drugs * Malignancies within the last 2 years * Known hematological, rheumatic and inflammatory diseases * Known chronic infections * Poorly controlled chronic cardiovascular and metabolic conditions * Pregnancy * Dementia
About the study
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
What is being tested
- vaccine (other)
Sponsor: State University of New York at Buffalo · Participants: 60 · Started: Jan 8, 2024
Contact the study team
- Elsa Bou Ghanem, PhD · Phone: 7168292422
Official record on ClinicalTrials.gov — NCT06128915
Locations in the U.S.
| New York | University at Buffalo, Buffalo |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.